Skip to content

13F-HR filed by Vivo Capital, LLC

Vivo Capital, LLC filed this 13F-HR for the quarter ended 2017-12-31, filed 2018-02-09, with 30 holding rows worth $466,864,000.

Accession
0001214659-18-001028
Filed
2018-02-09
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2017

A holdings report, 30 entries on the cover page, a total value of $466,864,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $466,864,000 with VALUE read as thousands by filing date, 13F file number 028-17467. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ASCENDIS PHARMA A/S DKK 1.0 AD04351P101SPONSORED ADR1,766,832$70,779,000thousands by filing date
BIOHAVEN PHARMACEUTICAL HOLDING11196105COM1,976,818$53,335,000thousands by filing date
ACLARIS THERAPEUTICS INC COM00461U105Stock1,647,214$40,620,000thousands by filing date
APELLIS PHARMACEUTICALS INC03753U106COM1,457,834$31,635,000thousands by filing date
CODEXIS INC192005106COM3,054,825$25,508,000thousands by filing date
EIGER BIOPHARMACEUTICALS INC28249U105COM1,791,257$24,988,000thousands by filing date
NABRIVA THERAPEUTICS PLCG63637105SHS4,074,190$24,364,000thousands by filing date
AIMMUNE THERAPEUTICS INC.00900T107Common Stock643,626$24,342,000thousands by filing date
KALA BIO INC COM483119103Stock1,158,911$21,428,000thousands by filing date
ADVANCED ACCELERATOR APPLIC SPONSORED ADS00790T100ADR249,241$20,343,000thousands by filing date
STRONGBRIDGE BIOPHARMA PLCG85347105SHS USD2,452,397$17,780,000thousands by filing date
VERONA PHARMA PLC925050106SPONSORED ADS1,492,951$17,723,000thousands by filing date
KADMON HLDGS INC48283N106COM3,333,333$12,067,000thousands by filing date
SELECTA BIOSCIENCES INC816212104COM1,119,189$10,979,000thousands by filing date
AMYRIS INC03236M200COM NEW2,826,711$10,600,000thousands by filing date
SIERRA ONCOLOGY INC82640U107COM2,438,270$9,095,000thousands by filing date
SOLENO THERAPEUTIVS, INC.834203200COMM4,033,534$7,260,000thousands by filing date
ZAI LAB LTD ADR98887Q104ADR317,567$6,742,000thousands by filing date
AURINIA PHARMACEUTICALS INC COM05156V102Stock1,213,290$5,496,000thousands by filing date
REGENXBIO INC75901B107COM164,403$5,466,000thousands by filing date
FOAMIX PHARMACEUTICALS LTDM46135105SHS855,000$5,139,000thousands by filing date
ZOGENIX INC.98978L204Common Stock105,000$4,205,000thousands by filing date
AGILE THERAPEUTICS INC00847L100COM1,513,975$4,073,000thousands by filing date
KALVISTA PHARMACEUTICALS INC483497103COM300,325$2,928,000thousands by filing date
TREVENA INC89532E109COM1,728,000$2,765,000thousands by filing date
CRISPR THERAPEUTICS AG NAMEN AKTH17182108Stock98,511$2,313,000thousands by filing date
SUNESIS PHARMACEUTICALS INC867328700COM500,000$1,845,000thousands by filing date
BIOPHARMX CORP09072X101COM13,799,944$1,521,000thousands by filing date
AKARI THERAPEUTICS PLC00972G108ADR345,850$1,498,000thousands by filing date
SOLENO THERAPEUTICS INC834203135*W EXP 11/12/201188,772$27,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001214659-18-001028this filing2018-02-09acceptance time not in the bulk data set